We are thrilled to announce that we will begin construction of a new, 145,000-square-foot cGMP facility in Philadelphia for the manufacture of cell therapy products. This facility is designed for cell therapy products that contain viral vectors such as chimeric antigen receptor T-cell (CAR T-cell) therapies. CAR T cells are T cells harvested from a patient’s body, engineered to target specific cancers, and then reintroduced into the body.
The new facility will become WuXi’s third cell therapy manufacturing facility when it becomes operational in mid 2016. It will provide single-source process development and cGMP manufacture capabilities to support the rapidly growing cellular therapeutic industry’s unique requirements. Our cell therapy manufacturing facilities will complement our current fully integrated service facility for biological safety and lot release testing in Philadelphia. Cell therapies like CAR T-cells offer important new treatment options for cancer patients, and we aim to be at the forefront of this area of cutting-edge science.